Clinical Trial: A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and Its Metabolites in Healthy Participants

U.S., Sept. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07840612) titled 'A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and Its Metabolites in Healthy Participants' on Sept. 18.

Brief Summary: This is a single-centre, open-label, fixed-sequence, 2-period study in healthy participants. The total study duration for each participant will be up to approximately 56 days, including a 28-day screening period, a 19-day assessment period (including Period 1 and Period 2), and a follow-up (FU) visit approximately 7 days after clinical research unit (CRU) discharge.

Study Start Date: Sept. 25

Study Type: INTERVENTIONAL

Condition: Healthy

Intervention: DRUG: Mirdametinib ...